Safety and efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA Foundation cohorts

Digestive and Liver Disease（2018）

引用 2|浏览79

暂无评分

摘要

DCV use resulted in high SVR rate regardless of dosage and correctness of prescription.

查看译文

关键词

Adequate prescription,Daclatasvir,Drug–drug interactions,DAA,HCV,HIV co-infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要